MAM
VTVT icon

Meeder Asset Management’s vTv Therapeutics VTVT Stock Holding History

Meeder Asset Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15
Closed -$944 – 1704
2018
Q2 		$944 Buy
+15
New +$1.11K ﹤0.01% 1508
2017
Q3 		– Sell
-20
Closed -$4K – 1776
2017
Q2 		$4K Hold
20
– – ﹤0.01% 1276
2017
Q1 		$5K Sell
20
-21
-51% -$4.79K ﹤0.01% 1101
2016
Q4 		$8K Buy
+41
New +$9.42K ﹤0.01% 800

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Meeder Asset Management's VTVT Position: Q3 2018 in Review

Meeder Asset Management sold out of vTv Therapeutics (VTVT) in Q3 2018, closing a stake of 15 shares — an estimated $944 sold.

Meeder Asset Management first reported a position in VTVT in Q4 2016 and held it in 4 quarters. The position peaked at $8K in Q4 2016. 19 funds tracked by Wall St. Rank hold VTVT as of Q3 2018.

  • Meeder Asset Management reported no remaining vTv Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Meeder Asset Management sold 15 vTv Therapeutics shares in Q3 2018, an estimated $944.
  • Meeder Asset Management first reported a position in vTv Therapeutics in Q4 2016 and held it in 4 quarters.
  • Meeder Asset Management's vTv Therapeutics position peaked at $8K in Q4 2016.
  • 19 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2018.

Based on Meeder Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.